Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)
China flag China · Delayed Price · Currency is CNY
57.78
+0.17 (0.30%)
Jul 29, 2026, 3:00 PM CST

SHA:688621 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
372.45462.17565.56690.93608.93490.25
Short-Term Investments
-8020---
Trading Asset Securities
4775303013.11157.6
Cash & Short-Term Investments
419.45617.17615.56720.93622.04647.85
Cash Growth
-37.45%0.26%-14.62%15.90%-3.98%492.70%
Accounts Receivable
1,034935.3774.96555.83362.73239.2
Other Receivables
7.496.6510.1611.2116.1712
Receivables
1,041941.95785.12567.04378.9251.21
Inventory
14.6714.0315.0514.4112.547.84
Prepaid Expenses
-----1.9
Other Current Assets
245.37167.4798.7654.7626.4832.99
Total Current Assets
1,7211,7411,5141,3571,040941.79
Property, Plant & Equipment
167.69177.91211.61220.26197.02161.05
Long-Term Investments
124.15179.29115.69100.7594.7540
Goodwill
20.5120.5126.0626.0626.0626.06
Other Intangible Assets
4.054.735.415.394.23.32
Long-Term Deferred Tax Assets
111.47102.2764.0438.9316.695.03
Long-Term Deferred Charges
27.6130.6448.2864.1976.2533.41
Other Long-Term Assets
123.9128.821.7350.318.7831.99
Total Assets
2,3002,2851,9871,8631,4641,243

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
60.9249.0930.6849.1222.1312.52
Accrued Expenses
22.1842.0253.6347.4437.2927.33
Short-Term Debt
508.93499.13309.39383.93201.17138.01
Current Portion of Long-Term Debt
34.6219.219.3---
Current Portion of Leases
-17.6324.7822.122.5418.98
Current Income Taxes Payable
40.6531.146.624.9216.9311.42
Current Unearned Revenue
284.87299.15321.43220.83205.85199.85
Other Current Liabilities
10.2911.2812.7612.8812.279.72
Total Current Liabilities
962.47968.65778.56761.21518.19417.83
Long-Term Debt
38.44867.2---
Long-Term Leases
26.729.7535.1240.6233.8449.72
Long-Term Unearned Revenue
3.573.572.523.592.835.46
Long-Term Deferred Tax Liabilities
0.020.051.250.350.24-
Other Long-Term Liabilities
1.281.28----
Total Liabilities
1,0321,051884.65805.76555.1473.01

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
1121121121128080
Additional Paid-In Capital
422.36406.54375.86474.17499.85499.85
Retained Earnings
819.46798.83612.78453.85317.09182.1
Treasury Stock
-100-100----
Total Common Equity
1,2541,2171,1011,040896.93761.95
Minority Interest
13.9216.122.0117.2511.677.69
Shareholders' Equity
1,2681,2331,1031,057908.6769.64
Total Liabilities & Equity
2,3002,2851,9871,8631,4641,243

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
608.65613.71455.79446.65257.55206.71
Net Cash (Debt)
-189.23.45159.77274.28364.48441.14
Net Cash Growth
--97.84%-41.75%-24.75%-17.38%414.12%
Net Cash Per Share
-1.710.031.422.453.264.50
Filing Date Shares Outstanding
109.28109.28112112112112
Total Common Shares Outstanding
109.28109.28112112112112
Working Capital
758.31771.97735.93595.93521.77523.96
Book Value Per Share
11.4711.149.839.298.016.80
Tangible Book Value
1,2291,1921,0691,009866.68732.57
Tangible Book Value Per Share
11.2510.919.559.017.746.54
Machinery
-261.43256.34232.62195.9124.14
Construction In Progress
-----3.4